Market Research Logo

Pol Polyprotein - Pipeline Review, H2 2016

Pol Polyprotein - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Pol Polyprotein - Pipeline Review, H2 2016’, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
  • The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
  • The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Pol Polyprotein
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Pol Polyprotein Overview
Therapeutics Development
Pol Polyprotein - Products under Development by Stage of Development
Pol Polyprotein - Products under Development by Therapy Area
Pol Polyprotein - Products under Development by Indication
Pol Polyprotein - Pipeline Products Glance
Late Stage Products
Early Stage Products
Pol Polyprotein - Products under Development by Companies
Pol Polyprotein - Products under Development by Universities/Institutes
Pol Polyprotein - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Pol Polyprotein - Companies Involved in Therapeutics Development
GeoVax Labs, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Pol Polyprotein - Drug Profiles
GOVXB-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GOVXC-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GOVXC-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine 11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine 5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVATG-17401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PENNVAX-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PENNVAX-GP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pol Polyprotein - Dormant Projects
Pol Polyprotein - Featured News & Press Releases
Oct 20, 2016: GeoVax HIV Vaccine Clinical Data Presented at HIVR4P Conference
Aug 02, 2016: GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials
Jul 14, 2016: Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV
Jun 30, 2016: GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial
May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11
Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant
Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates
Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine
Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine
Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress
Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program
Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases
Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV
Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data
Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by GeoVax Labs, Inc., H2 2016
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
Pipeline by Johnson & Johnson, H2 2016
Dormant Projects, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report